Active/Enrolling:
Rebiotix
- Principal Investigator: Gary Wang, MD, PhD
- https://clinicaltrials.gov/ct2/show/NCT03931941
- The purpose of this study is to evaluate safety and tolerability of Rebiotix (RBX2660) in outpatient subjects with recurrent Clostridium difficile infection (CDI) who have had prior recurrent CDI that was resolved with another antibiotic treatment. Rebiotix is aimed towards patients who have had at least one recurrence of CDI after a primary episode and have completed at least one round of standard of care antibiotic therapy or at least two episodes of severe CDI requiring hospitalization.
- Contact: Evan Waters, 352-294-5885, waterse@ufl.edu
Closed to Enrollment:
None at this time; please check back soon.
Pending:
PRISM-4
- Principal Investigator: Gary Wang, MD, PhD
- https://clinicaltrials.gov/ct2/show/study/NCT05153499
- The goal of this outpatient study is to evaluate the safety and efficacy of CP101 as a preventative measure of recurrent Clostridium difficile infection (CDI). CP101 is an investigational microbiome drug, and is being studied due to its design to deliver a complete and functional microbiome to durably repair intestinal dysbiosis. This study contains two parts; a randomized, double-blind, placebo-controlled arm and an optional open-label treatment arm.
- Contact: Evan Waters, 352-294-5885, waterse@ufl.edu